NASDAQ:CELG - Celgene Stock Price, News, & Analysis

$96.51
+0.07 (+0.07 %)
(As of 06/14/2019 04:00 PM ET)
Today's Range
$96.20
Now: $96.51
$97.15
50-Day Range
$93.66
MA: $95.28
$96.88
52-Week Range
$58.59
Now: $96.51
$97.15
Volume3.14 million shs
Average Volume4.07 million shs
Market Capitalization$68.06 billion
P/E Ratio12.68
Dividend YieldN/A
Beta1.57
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CELG
CUSIP15102010
Phone908-673-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.28 billion
Cash Flow$8.8786 per share
Book Value$8.79 per share

Profitability

Net Income$4.05 billion

Miscellaneous

Employees8,852
Market Cap$68.06 billion
Next Earnings Date7/25/2019 (Estimated)
OptionableOptionable

Receive CELG News and Ratings via Email

Sign-up to receive the latest news and ratings for CELG and its competitors with MarketBeat's FREE daily newsletter.

Celgene (NASDAQ:CELG) Frequently Asked Questions

What is Celgene's stock symbol?

Celgene trades on the NASDAQ under the ticker symbol "CELG."

When did Celgene's stock split? How did Celgene's stock split work?

Celgene's stock split on the morning of Thursday, June 26th 2014. The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were payable to shareholders after the market closes on Wednesday, June 25th 2014. An investor that had 100 shares of Celgene stock prior to the split would have 200 shares after the split.

How will Celgene's stock buyback program work?

Celgene declared that its Board of Directors has authorized a share buyback program on Thursday, May 24th 2018, which authorizes the company to buyback $3,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 5.4% of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board believes its shares are undervalued.

How were Celgene's earnings last quarter?

Celgene Co. (NASDAQ:CELG) released its quarterly earnings data on Thursday, April, 25th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $2.45 by $0.10. The biopharmaceutical company earned $4.03 billion during the quarter, compared to analyst estimates of $4.01 billion. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The company's revenue for the quarter was up 13.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 earnings per share. View Celgene's Earnings History.

When is Celgene's next earnings date?

Celgene is scheduled to release their next quarterly earnings announcement on Thursday, July 25th 2019. View Earnings Estimates for Celgene.

What guidance has Celgene issued on next quarter's earnings?

Celgene issued an update on its FY19 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of $10.60-10.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.70. The company issued revenue guidance of $17.0-17.2 billion, compared to the consensus revenue estimate of $17.10 billion.

What price target have analysts set for CELG?

20 brokers have issued twelve-month price objectives for Celgene's stock. Their predictions range from $77.00 to $112.00. On average, they anticipate Celgene's share price to reach $95.31 in the next year. This suggests that the stock has a possible downside of 1.2%. View Analyst Price Targets for Celgene.

What is the consensus analysts' recommendation for Celgene?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celgene in the last year. There are currently 16 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Celgene.

What are Wall Street analysts saying about Celgene stock?

Here are some recent quotes from research analysts about Celgene stock:
  • 1. According to Zacks Investment Research, "Celgene’s key growth driver, Revlimid continues to drive revenues. Robust performance of psoriasis drug, Otezla is also boosting performance. Investors are focusing on the company’s recent merger agreement with Bristol-Myers Squibb Company. Per the terms, Celgene shareholders will receive 1.0 share of Bristol-Myers and $50.00 in cash for each share held. Though the acquisition is yet to be approved, the company will get a respite from the same, having faced a series of pipeline setbacks in recent times. Meanwhile, Celgene is also working on label expansion of drugs like Pomalyst/Imnovid, Abraxane and Otezla, among others. The company is focused on the next cycle of innovation with five late-stage candidates — ozanimod, fedratinib, luspatercept, liso-cel and bb2121 — all of which are expected to be launched by the end of 2020. Shares have outperformed the industry in the past three months." (4/3/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $100 12-month price target. Celgene reported a strong 4Q this morning and issued full year 2019 guidance. 4Q revs of ~$4B beat us and consensus on the top line, while adj. EPS of $2.39 also came in above us and consensus at $2.33 and $2.32. Base business trends were surprisingly strong, and management reiterated timelines for all five late- stage pipeline products on track for approval by the end of 2020. We think the key takeaway from the call was that commercial and pipeline execution appear to be back on track with a clear line of sight to the Bristol (BMY, NC) deal closing in 3Q19. We think guidance for 2019 seems conservative." (1/31/2019)
  • 3. Mizuho analysts commented, "We updated our model post the 2Q18 earnings call. Here are the key changes we made: ===Upward Revisions=== 1. bb2121. Added bb2121 to pipeline section of the model ($1Bn in risk- adjusted peak sales to CELG vs consensus of $900MM) 2. Luspatercept. Increased POS from 67% to 90% on the back of the recent positive Ph 3 results. (peak risk-adj sales now of $1Bn, ex-royalty to XLRN …. consensus at $850MM) ===Downward Revisions=== 3. Ozanimod MS. Trimmed peak risked adjusted sales from $1.3Bn to $1.1Bn. In total, across all 3 indications (MS, UC, CD), we carry $2.8Bn (vs consensus of $2.5Bn)." (7/31/2018)
  • 4. Cowen Inc analysts commented, "We will be hosting a conference call with neurologist to discuss and TD-9855. Theravance is evaluating 1/2 trial in patients with . Results are expected to be available this month." (7/10/2018)

Has Celgene been receiving favorable news coverage?

Media stories about CELG stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Celgene earned a news impact score of -1.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Celgene.

Are investors shorting Celgene?

Celgene saw a decline in short interest during the month of April. As of April 30th, there was short interest totalling 11,471,278 shares, a decline of 16.7% from the April 15th total of 13,774,728 shares. Based on an average trading volume of 6,459,289 shares, the short-interest ratio is currently 1.8 days. Currently, 1.6% of the shares of the company are sold short. View Celgene's Current Options Chain.

Who are some of Celgene's key competitors?

What other stocks do shareholders of Celgene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Celgene investors own include Akorn (AKRX), Gilead Sciences (GILD), NVIDIA (NVDA), Bank of America (BAC), Skechers USA (SKX), Alibaba Group (BABA), Integrated Device Technology (IDTI), Netflix (NFLX), Micron Technology (MU) and Intel (INTC).

Who are Celgene's key executives?

Celgene's management team includes the folowing people:
  • Mr. Mark J. Alles, Chairman & CEO (Age 60)
  • Mr. David V. Elkins, Exec. VP & CFO (Age 50)
  • Mr. Peter N. Kellogg, Exec. VP & Chief Corp. Strategy Officer (Age 63)
  • Dr. S. J. Rupert Vessey MA, BM BCh, FRCP, DPhil, Pres of Research & Early Devel. (Age 54)
  • Dr. Alise Reicin M.D., Pres of Global Clinical Devel. (Age 58)

Who are Celgene's major shareholders?

Celgene's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.36%), FMR LLC (2.36%), Geode Capital Management LLC (1.33%), Northern Trust Corp (1.28%), Abrams Capital Management L.P. (0.96%) and Janus Henderson Group PLC (0.74%). Company insiders that own Celgene stock include Ernest Mario, Gilla Kaplan, James J Loughlin, John H Weiland, Mark J Alles, Michael A Friedman, Michael D Casey, Robert J Hugin, Rupert Vessey and Terrie Curran. View Institutional Ownership Trends for Celgene.

Which major investors are selling Celgene stock?

CELG stock was sold by a variety of institutional investors in the last quarter, including Clearbridge Investments LLC, Janus Henderson Group PLC, Jennison Associates LLC, AQR Capital Management LLC, Bank of Montreal Can, Parnassus Investments CA, BlackRock Inc. and OppenheimerFunds Inc.. Company insiders that have sold Celgene company stock in the last year include Ernest Mario and James J Loughlin. View Insider Buying and Selling for Celgene.

Which major investors are buying Celgene stock?

CELG stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Abrams Capital Management L.P., Renaissance Technologies LLC, Ruffer LLP, Alpine Associates Management Inc., Boussard & Gavaudan Investment Management LLP, Third Point LLC and OZ Management LP. Company insiders that have bought Celgene stock in the last two years include Ernest Mario, John H Weiland and Mark J Alles. View Insider Buying and Selling for Celgene.

How do I buy shares of Celgene?

Shares of CELG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celgene's stock price today?

One share of CELG stock can currently be purchased for approximately $96.51.

How big of a company is Celgene?

Celgene has a market capitalization of $68.06 billion and generates $15.28 billion in revenue each year. The biopharmaceutical company earns $4.05 billion in net income (profit) each year or $7.61 on an earnings per share basis. Celgene employs 8,852 workers across the globe.View Additional Information About Celgene.

What is Celgene's official website?

The official website for Celgene is http://www.celgene.com/.

How can I contact Celgene?

Celgene's mailing address is 86 MORRIS AVENUE, SUMMIT NJ, 07901. The biopharmaceutical company can be reached via phone at 908-673-9000 or via email at [email protected]


MarketBeat Community Rating for Celgene (NASDAQ CELG)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  1,963 (Vote Outperform)
Underperform Votes:  730 (Vote Underperform)
Total Votes:  2,693
MarketBeat's community ratings are surveys of what our community members think about Celgene and other stocks. Vote "Outperform" if you believe CELG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CELG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/15/2019 by MarketBeat.com Staff

Featured Article: What is a Call Option?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel